Hostname: page-component-788cddb947-kc5xb Total loading time: 0 Render date: 2024-10-13T05:35:17.357Z Has data issue: false hasContentIssue false

S20-01 - Parathyroid Hormone and Cognitive Deficits in Lithium-Treated Bipolar Patients

Published online by Cambridge University Press:  17 April 2020

E. Severus
Affiliation:
Psychiatry, LMU University of Munich, Munich, Germany
K. Fast
Affiliation:
Psychiatry, LMU University of Munich, Munich, Germany
N. Tomova
Affiliation:
Psychiatry, LMU University of Munich, Munich, Germany
M. Berger
Affiliation:
Psychiatry, LMU University of Munich, Munich, Germany
M. Obermeier
Affiliation:
Psychiatry, LMU University of Munich, Munich, Germany
F. Seemüller
Affiliation:
Psychiatry, LMU University of Munich, Munich, Germany
S. Dittmann
Affiliation:
Psychiatry, LMU University of Munich, Munich, Germany
B. Bernhard
Affiliation:
Psychiatry, LMU University of Munich, Munich, Germany
H.-J. Möller
Affiliation:
Psychiatry, LMU University of Munich, Munich, Germany
M. Riedel
Affiliation:
Psychiatry, LMU University of Munich, Munich, Germany

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Long-term lithium-treatment has been associated with deficits in several cognitive domains in euthymic bipolar patients. At the same time, long-term lithium treatment is also associated with an increase in parathyroid levels, often without a concomitant increase in calcium levels. Such an isolated increase in parathyroid levels has been linked to depressive symptoms and cognitive deficits in otherwise healthy individuals.

Aims

To investigate whether increased parathyroid levels are associated with cognitive deficits in euthymic bipolar patients.

Methods

We plan to recruit 30 euthymic bipolar patients on lithium treatment for this study. Patients will take part in several neuropsychological tests, covering executive functioning, memory and attention. In parallel, blood levels of lithium, parathyroid hormone, 25-hydroxyvitamin D, creatinine, calcium and phosphate will be assessed, besides clinical chemistry and blood cell count. In addition, to account for potential confounders, a variety of clinical variables will be recorded, including established mood rating scales and demographic variables as well as further parameters relevant to the course of the illness.

Results

As the study is still ongoing results are not available yet at this moment.

Discussion

Results will be discussed in the context of previous studies examining the impact of lithium and parathyroid hormone on mood and cognition in healthy individuals and patients with bipolar disorder, respectively. Dependent on the outcome of this study, potential future studies, including intervention trials aiming at lowering increased PTH levels in bipolar patients on lithium will be outlined.

Type
Cognitive Functioning in Bipolar Disorders: an update
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.